GAVRETO (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson

September 17, 2020

CARY, N.C., Sept. 17, 2020 Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETOTM (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

GAVRETO, which was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 4, 2020, was specifically designed to inhibit RET alterations. RET fusions are oncogenic drivers for multiple solid tumor types. This drug was given priority review by the FDA, which is granted to drugs that are expected to have a large impact on a disease’s treatment.

“GAVRETO gives patients a new RET inhibitor option for treating their RET-driven metastatic NSCLC,” said Allison Kinnarney, director of Clinical Programs with Biologics. “Patients with RET fusion-positive NSCLC usually have limited benefit from immunotherapy, and GAVRETO is a much-needed alternative for patients. We’re excited to be chosen by Blueprint Medicines to help make this therapy available.”

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.


Blueprint Medicines and GAVRETO are trademarks of Blueprint Medicines Corporation.

Public Relations Contact